“…Partly this has been due to the systematic distortion of the evidence base and other abuses committed by the pharmaceutical industry (Angell 2005;Every-Palmer and Howick 2014). Recently, the rhetoric surrounding COI reporting has increased to a boiling point, marked by heavy debate and diametrically opposed positions over what COIs are, what effects they are likely to engender, and how they should be managed-if at all (Acquavella and Ramlow 1997;Cappola and FitzGerald 2015;Elliot 2014;Fineberg 2017;Fontanarosa and Bauchner 2017;Johnson and Horn 2010;Lee [44.224.250.200] Project MUSE (2024-06-03 15:52 GMT) KENNEDY INSTITUTE OF ETHICS JOURNAL • MARCH 2022 [ 104 ] 2008; Loewenstein, Sah, and Cain 2012;Mayes, Lipworth, and Kerridge 2015;McKinney and Pierce 2017;Mintzes and Grundy 2018;Psaty 2009;Resnik and Elliot 2013;Rosenbaum 2015aRosenbaum , 2015bRosenbaum , 2015cRothman 1993;Steinbrook, Kassierer, and Angell 2015;Stossel 2008;Stossel, Barton, and Stell 2015;Tarone 2018;Wiersma et al 2018a, b). More and more journals require disclosure, and recommendations have been made that religious (Smith and Blazeby 2018), dietary (Ioannidis and Trepanowski 2018), and other non-financial disclosures be added to the list of financial disclosures (Wiersma et al 2018a, b).…”